August 2012 Editor's Picks: Products from Getinge and MG America - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

August 2012 Editor's Picks: Products from Getinge and MG America

Equipment and Processing Report

August 2012 Editor's Picks: Products from Getinge and MG America
Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Getinge

Rigid-wall isolators improve productivity of sterility testing.
Sterility testing in an isolator helps avoid false-positive or false-negative results, and Getinge-La Calhène’s Isotest stainless-steel, rigid-wall isolators are designed to improve the workflow for sterility testing of injectables. The Isotest is equipped with one or two workstations in the same chamber, an attached fast decontamination chamber, and Getinge’s DPTE transfer system to evacuate the test canister and solid/liquid waste. The Isotest integrated bio-decontamination system is self-contained. Isotest can bio-decontaminate either the working chamber or the fast-decontamination chamber using the Isotest PLC control-system touch screen. Hydrogen peroxide is delivered from a canister that includes an RFID chip, which allows the PLC to monitor the volume and remaining shelf life, thus providing full traceability.


MG America
Versatile capsule filler with multiple dosing units is designed for small runs.

MG America’s FlexaLAB capsule filler, which can produce up to 3000 capsules per hour, is designed for research and development, clinical trials, and small-batch production. The FlexaLAB can function with either continuous or intermittent motion. Installing multiple dosing units allows the FlexaLAB to manufacture capsules with combinations of products. The machine can fill powders, pellets, microtablets, tablets, liquids, and certain low-dosage powder inhalants and can perform capsule-into-capsule functions. The machine includes a touch-screen panel and PLC for machine-functions control. Machine speed can be adjusted from the monitor.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Equipment and Processing Report,
Click here